Introduction
Clinical trials used to evaluate treatments for schizophrenia can be broadly categorized as explanatory or pragmatic (Thorpe et al., 2009; Roland and Torgerson, 1998) . Explanatory clinical trials for pharmaceuticals generally focus on specific questions related to efficacy and safety of the targeted compound. This focus usually requires that such trials be completed in relatively homogenous study populations under welldefined and highly controlled conditions so that external factors (e.g., comorbid diseases) do not confound interpretation of results (Thorpe et al., 2009; Roland and Torgerson, 1998; Alphs et al., 2014b) . In contrast, pragmatic trials typically address the question, "How well does the treatment work in actual practice?" Such trials often compare treatment response (both safety and efficacy) in more heterogeneous study populations with few treatment restrictions outside of those encountered in actual clinical practice. They are often conducted with an active comparator that is used only under the constraints of actual practice (Thorpe et al., 2009; Roland and Torgerson, 1998) . Both explanatory and pragmatic clinical trials address important questions. However, because pragmatic trials more closely replicate actual clinical practice, their results are more broadly generalizable (Alphs and Bossie, in press; Bossie et al., in press; Alphs et al., 2014b) . The PRIDE study design had both explanatory and pragmatic features. Results of the explanatory analysis, which demonstrated that treatment with PP significantly delayed treatment failure versus daily OAs, have been previously reported (Alphs et al., 2015) , with a median difference in time to treatment failure of 190 days over a 15-month period of observation (P = 0.011).
To retain study subjects and to facilitate the interpretation of safety and efficacy results, explanatory trials typically exclude complex patients, such as those with comorbid substance abuse, suboptimal Schizophrenia Research 170 (2016) 
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Schizophrenia Research j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / s c h r e s disease management, and contact with the CJS. This approach represents a significant limitation to the generalizability and interpretation of results of many schizophrenia trials because the exclusionary criteria represent common conditions that are not evaluated. Such excluded patients may be of particular interest to population health decisionmakers as well as clinicians because these patients are more likely to be high resource utilizers with poor treatment adherence (AscherSvanum et al., 2010; Hunt et al., 2002; Wilk et al., 2006) , have increased risk of symptom relapse, and be more frequently institutionalized (Morken et al., 2008; Kane, 2011) . Another area of interest to clinical and population health stakeholders is whether patients with schizophrenia treated with long-acting injectable (LAI) antipsychotic therapies have better outcomes than those treated with daily oral antipsychotic (OA) therapies. The literature regarding this question is conflicting (Fusar-Poli et al., 2013; Kirson et al., 2013; Kishimoto et al., 2013 Kishimoto et al., , 2014 . With these considerations in mind, the PRIDE study (NCT01157351) was designed to address a number of pragmatic questions. The study included patients typically excluded from antipsychotic treatment trials (i.e., those with a history of recent incarceration and comorbid substance abuse), allowed flexible treatment management decisions, and selected endpoint measures representing clinically important outcomes (e.g., hospitalization, treatment discontinuation due to arrest/incarceration) (Alphs et al., 2014a) . The study design also encouraged study participation after an initial treatment failure event, permitting evaluation of cumulative treatment failures during the entire trial period. This characteristic provides important clinical information on outcomes within a defined period that is important for population health decision-making (Alphs et al., 2014a; Bossie et al., in press; Alphs and Bossie, in press ). The pragmatic analysis included all data related to treatment failures from randomization until the end of the 15-month period regardless of whether subjects were maintained on their initial randomized treatment. This allowed for comparison of long-term consequences of treatment strategies.
Methods

Study design
As described elsewhere (Alphs et al., 2014a (Alphs et al., , 2015 , PRIDE was a prospective, randomized, open-label, active-controlled, multicenter US study conducted between May 5, 2010, and December 9, 2013. The study consisted of a screening phase of up to 2 weeks, followed by a 15-month randomized treatment phase.
Subjects
The study included adults aged 18 to 65 years with a current diagnosis of schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV] criteria) (American Psychiatric Association, 2000) confirmed by the MINI-International Neuropsychiatric Interview (MINI), version 6.0 (Sheehan et al., 1998) . Additional inclusion criteria were recent history of custody by the CJS (at least twice in the previous 2 years, with at least one instance leading to incarceration). Release from the most recent custody must have occurred within 90 days of screening. Substance abuse was not an exclusionary factor for participation, but subjects were excluded if they were actively abusing intravenous drugs within the past 3 months or had an opiate dependence disorder. Additional major exclusion criteria were use of clozapine within 3 months of screening or use of an injectable antipsychotic within two injection cycles of screening. The study was approved by the institutional review board at each site and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all subjects.
Treatments
Patients were randomly assigned to treatment with PP or an OA medication (i.e. aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, or risperidone). Of the seven OAs, up to six could be deselected prior to randomization if they were deemed unacceptable by the patient or clinician. Subjects were stratified on the basis of selection of OA treatments and were randomly assigned (1:1) to flexibly dosed, monthly PP (78-234 mg) or flexibly dosed, daily OA therapy. If necessary, subjects could be switched to another oral medication during the 15-month study period.
Outcomes
The primary endpoint for this pragmatic analysis was the mean number of treatment failures during the 15-month period. "Treatment failure" represented a composite measure consisting of any of the following events: arrest or incarceration; psychiatric hospitalization; suicide; discontinuation of treatment due to inadequate efficacy, safety, or tolerability; treatment supplementation with another antipsychotic due to inadequate efficacy; or increase in psychiatric services to prevent imminent psychiatric hospitalization. A secondary endpoint for this pragmatic analysis was the mean number of institutionalizations (arrests or incarcerations and/or psychiatric hospitalizations) over the 15-month period.
Statistical analysis
This pragmatic analysis included all data from the intent-to-treat (ITT) population, defined as all randomly assigned subjects who received ≥1 dose of study treatment. The analysis set included data available from randomization until month 15. Demographics, baseline characteristics, and treatment-emergent adverse events (TEAEs) were summarized in the primary analysis using descriptive statistics (Alphs et al., 2015) . Multiple treatment failures in the same subject were analyzed as recurrent events and were used to estimate the mean cumulative function (MCF) (Nelson, 2002) . The MCF is a function of time, defined as the mean number of events at time t following randomization (Nelson, 2002) . The MCF at the 12-month time point can be interpreted as the mean number of events per person-year follow-up. The MCF for number of treatment failures and the MCF for number of institutionalizations were compared between the two treatment groups using a proportional intensity model that included a term for treatment and indicator variables for three baseline prognostic covariates: multiple prior incarcerations, history of substance abuse, and being randomized to the antipsychotic medication taken prior to study entry. These three covariates are clinically meaningful and were identified through systemic model selection procedures. Inclusion of these prognostic covariates in the model allows more precise estimation of treatment effect.
Results
Subjects and disposition
Of the 693 subjects screened, 450 were randomized to treatment with PP (n = 230) or daily OAs (n = 220), and 444 subjects were included in the ITT population (PP, n = 226; OAs, n = 218) (Alphs et al., 2015) . There were 181 subjects (40.8%) who completed the full 15-month study period (93 in the PP group; 88 in the OA group) (Fig.  1) . Demographic and baseline clinical characteristics appeared similar between both treatment groups. The majority of subjects were male (86.3%) and black/African American (62.1%), with an overall mean (standard deviation) age of 38.1 (10.47) years (Alphs et al., 2015) . During the treatment period, a similar proportion of patients switched study medication once (PP, 8.8%; OAs, 10.1%), twice (PP, 1.8%; OAs, 0.9%), or three times (PP, 0%; OAs, 0.9%).
Efficacy outcomes
The covariate-adjusted MCF for the number of treatment failures during the 15-month study period was significantly lower during treatment with PP versus OAs (P = 0.007; Fig. 2 ). The covariate-adjusted MCF (standard error [SE] ) for the number of treatment failure events at month 15 was 1.02 (0.111) in the PP group and 1.50 (0.145) in the OA group. The MCF at month 12 (mean number of any treatment failure events per person year of follow-up) was 0.87 (0.096) in the PP group and 1.28 (0.126) in the OA group.
The covariate-adjusted MCF for the number of institutionalizations (arrests or incarcerations or psychiatric hospitalizations) during the study period was significantly lower during treatment with PP versus OAs (P = 0.005; Fig. 3 ). The covariate-adjusted MCF (SE) for the number of institutionalizations at month 15 was 0.82 (0.095) in the PP group and 1.27 (0.132) in the OA group.
When the secondary endpoint (MCF for number of institutionalizations) was further delineated, the covariate-adjusted MCF for number of arrests or incarcerations during the study period was significantly lower during treatment with PP versus OAs (P = 0.011; Fig. 4A ). The difference in the covariate-adjusted MCFs for number of psychiatric hospitalizations approached but did not reach statistical significance during treatment with PP versus OAs (P = 0.074; Fig.  4B ). The covariate-adjusted MCF (SE) for number of arrests or incarcerations at 15 months was 0.67 (0.081) in the PP group and 0.98 (0.091) in the OA group; and the covariate-adjusted MCF for number of psychiatric hospitalizations was 0.15 (0.037) in the PP group and 0.29 (0.075) in the OA group.
Safety
Safety data from the PRIDE study, including adverse events (AEs) occurring from the time of randomization until the end of randomly assigned treatment, have been previously published (Alphs et al., 2015) . Here, all safety data observed during the 15-month follow-up (including those identified after patients switched to alternative treatments or after additional therapies were added) are provided. Overall, TEAEs were reported by 86.3% of subjects in the PP group and 81.7% in the OA group. TEAEs leading to treatment discontinuation occurred in 12.4% of subjects in the PP group and 8.7% of subjects in the OA group, with the most common being schizophrenia exacerbation in 0.4% of patients in the PP group and 2.3% in the OA group. Serious TEAEs occurred in 18.6% of PP subjects and 24.3% of OA subjects. One death was reported in the PP group, but it was considered by the investigator to be "unlikely related to the study medication." A summary of most frequent TEAEs that occurred during the randomized treatment period in the PP and OA groups are provided in the primary publication (Alphs et al., 2015) .
Discussion
Results of this analysis, which evaluated the number of treatment failure events in a defined interval (15 months), support the primary outcome of the PRIDE trial (Alphs et al., 2015) , and build evidential support that once-monthly PP treatment is associated with a more robust treatment effect than OA therapy in persons with schizophrenia who had recent contact with the CJS. Because healthcare costs track with major treatment failure events like hospitalization and incarceration, identification of all treatment failure events during a defined interval is helpful to providers, payers, and all those responsible for efficient management of our healthcare system. Pragmatic trials typically use objective outcome measures that are intuitively meaningful to most stakeholders, including the patient, caregivers, and public health officials (Alphs et al., 2014b) . To that end, the study used "treatment failure" as the key endpoint measure, which included highly objective and real-world outcome components. Further, pragmatic studies generally follow all subjects for the predefined interval, regardless of whether they remain on assigned treatment (Alphs et al., 2014b) . Consistent with this pragmatic approach, participants in the PRIDE study were encouraged to continue study participation, even after they experienced a potential treatment failure event. This allowed for the assessment of cumulative events of the predefined treatment failure endpoint in each treatment group during the full 15-month period of observation. It is noteworthy that the greatest observed advantage of PP over OAs was on efficacy measures, which have the greatest impact on the patient and for overall public health. That is, the most frequent treatment failures were due to various forms of institutionalization, on which PP-treated patients responded more favorably than OA-treated patients. Indeed, these high-risk patients with a history of recent incarceration were more likely to experience another arrest or incarceration as a treatment failure event than a hospitalization or change in medications. This is consistent with the high rates of incarceration of the mentally ill in the United States. Taken together, these results are supportive of published literature indicating that patients on OAs are at high risk for treatment failure (i.e., arrest, incarceration, or hospitalization) and that this is likely due to inadequate adherence to their daily oral medication resulting in reduced efficacy (Morken et al., 2008; Lindenmayer et al., 2009; Kane, 2011) .
Incarcerations are sometimes considered a reflection of antisocial rather than psychotic behaviors. Given that this study finds that differential pharmacologic intervention influences future events, these data suggest that risk for reincarceration or arrest is driven more by symptoms of schizophrenia than by antisocial tendencies.
These results further suggest that in customary practice, clinicians have difficulty proactively identifying when to intervene in this patient population to prevent impending institutionalization. The clinicians participating in this study saw patients monthly and were encouraged to intervene early to prevent negative outcomes, especially psychiatric hospitalizations or arrests. Nevertheless, institutionalizations were the most common treatment failure events. It seems likely that one driver of the differential response between PP and OAs was superior treatment coverage during LAI treatment because this approach eliminated the need for daily administration and provided certainty that the medication had been taken (Kane, 2011) .
The PRIDE study has a number of limitations. In particular, the population enrolled does not represent a random sample of all persons with schizophrenia. The requirement that participants have a history of recent incarceration likely selects for persons who are at particular risk for poor treatment adherence and reinstitutionalization. Similarly, practice settings were not randomly selected and may not be representative of real-world practice. Clinical groups participating in this study had to be familiar with conducting research and have experience with all the medications available for the study, especially long-acting injectable medications that have seen limited use in the United States. As a result, the level of patient oversight provided at study centers may have been greater than the care that is generally available in real-world practice. This might suggest that the results of this study underrepresent differences between PP and OA seen under completely naturalistic circumstances.
A statistical limitation is that estimation of the average number of some components of treatment failure events could be biased due to the issue of competing risk. For example, incarcerated patients would not be at risk for psychiatric hospitalization during their incarceration. Consequently, the risk for psychiatric hospitalization could be underestimated.
The pragmatic analysis included all data from the ITT population to better inform real-world practice, but this also resulted in confounds to interpretation in that patient data were analyzed according to their assigned treatment arm. Thus, although some patients switched from their randomly assigned treatment (10.6% of subjects switched from PP to OA; patients needing to switch to PP were discontinued from the study), all data collected for each patient were attributed to the randomly assigned treatment group. Treatment failure events and safety events occurring after a medication switch are likely to reflect response to new treatment and not their originally assigned treatment. Also, given the varied safety profiles for the various oral agents used for this study, the pooled safety data may have masked tolerability issues associated with individual medication. More importantly, the ability to deselect medications prior to randomization biases safety outcomes and treatment failures due to safety considerations in favor of OAs because safety concerns were the most common reason for the deselection of oral treatment.
Although efforts were made to follow all patients for a full 15 months, there was a gradual drop in subject participation as the study progressed. Our statistical approach sought to minimize the impact of these missing data, but we cannot be sure that all missing events were missing at random. Another consideration relates to the lack of blinding for ascertainment of treatment failure events. All treatment failures used in this pragmatic analysis were identified and reported by investigators who were not blinded to their study medication. This limitation is mitigated by the fact that most treatment failure events (i.e., incarcerations, arrests, and hospitalizations) were highly objective and likely not impacted by clinician knowledge of treatment. Furthermore, the first treatment failure for the primary explanatory analysis (Alphs et al., 2015) was determined by a blinded event-monitoring board. There was little difference in timing or number of events when determined by these blinded raters. Finally, the study was not powered to detect differences for the individual component of treatment failure events. The average numbers reported for specific treatment failure events gives some indication of relative risk, but a failure to demonstrate significance does not imply lack of clinical or societal relevance.
The literature comparing oral and long-acting injectable antipsychotic treatment approaches have produced disparate results with respect to their relative value (Alphs et al., 2014b; Fusar-Poli et al., 2013; Kirson et al., 2013; Kishimoto et al., 2013 Kishimoto et al., , 2014 . It has been suggested that differences in study design might be responsible for some of these disparate findings. This study provides strong evidence for superior outcomes with once-monthly PP in persons with schizophrenia and a history of CJS contact. Two different analytic approaches, using different but related data sets, both support this contention. Thus, in conclusion, this pragmatic analysis of PRIDE study data supports the previously reported primary explanatory findings and demonstrates that selection of injectable PP as a treatment strategy can reduce the total number of treatment failures over a period of 15 months compared with the selection of daily OAs in persons with schizophrenia and a history of CJS contact.
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